When a new phenomenon is reported, despite many previous reports on larger cohorts of patients, one naturally asks why the finding is novel. Is this a new phenomenon, or merely identified because one is looking carefully for it for the first time? This commentary explores possible reasons for the novel finding of essential thrombocythemia emerging in a cohort of Nucleophosmin 1 (NPM1)-mutated acute myeloid leukaemia (AML) patients. Commentary on: Bertoli et al., ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease. Brit J Haematol 2025;207:2153-2157.
Journal article
2025-11-01T00:00:00+00:00
207
2231 - 2232
1
AML, commentary, essential thrombocythemia, Humans, Nucleophosmin, Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins